This pattern of delayed response is peculiar of anti-CTLA4 antibodies and is the reason why novel immune-related response criteria were developed, according to which progressive disease is defined as an increase ≥25% in the sum of tumor diameters confirmed by two scans at least 4 weeks apart. This evidence concerns the gene CTLA4 and neoplasm.